T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

Our body's own defense system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumor ...

Cellecta, Inc., Mountain View, CA.

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

We have developed a versatile method for generating tolerogenic antigen-presenting cells in vivo by delivering mRNA encoding PDL1 via lipid nanoparticles. These tolerogenic antigen-presenting ...

New hope: MHH researchers are mobilising the immune system's defence against tumour cells within just two weeks using a two-phase vaccination regimen.

Johns Hopkins University School of Medicine, Baltimore, MD.

In a patient with treatment-refractory idiopathic inflammatory myositis, re-infusion of CD19 CAR-T cells following disease relapse led to the development of anti-CD19 CAR T cells and no clinical ...